Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: A randomised non-inferiority trial

Lancet

Volumn 366, Issue 9495, 2005, Pages 1435-1442

  Kullberg, B J ^a   Sobel, J D ^b   Ruhnke, M ^c   Pappas, P G ^d   Viscoli, C ^e   Rex, J H ^f   Cleary, J D ^g   Rubinstein, E ^h   Church, L W P ⁱ   Brown, J M ^j   Schlamm, H T ^k   Oborska, I T ^l   Hilton, F ^l   Hodges, M R ^l  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HUMBOLDT UNIVERSITY   (Germany)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF GENOA   (Italy)

^f UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MISSISSIPPI   (United States)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^k Pf Izer Global Research and Development   (United States)

^l PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CULTURE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA TROPICALIS; CANDIDIASIS; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEVER; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; VISUAL DISORDER; VOMITING;

EID: 26944446579     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)67490-9     Document Type: Article

References (21)

1. JH Rex, JE Bennett, AM Sugar A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia N Engl J Med 331 1994 1325 1330
2. P Phillips, S Shafran, G Garber Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients Eur J Clin Microbiol Infect Dis 16 1997 337 345
3. C Viscoli, C Girmenia, A Marinus Candidemia in cancer patients: a prospective, multicenter surveillance study in Europe by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC) Clin Infect Dis 28 1999 1071 1079
4. JE Edwards Jr, GP Bodey, RA Bowden International conference for the development of a consensus on the management and prevention of severe candidal infections Clin Infect Dis 25 1997 43 59
5. J Mora-Duarte, R Betts, C Rotstein Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
6. PG Pappas, JH Rex, JD Sobel Guidelines for treatment of candidiasis Clin Infect Dis 38 2004 161 168
7. MA Pfaller, DJ Diekema, RN Jones International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program J Clin Microbiol 39 2001 3254 3259
8. DW Bates, L Su, DT Yu Mortality and costs of acute renal failure associated with amphotericin B therapy Clin Infect Dis 32 2001 686 693
9. DW Denning, P Ribaud, N Milpied Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis Clin Infect Dis 34 2002 563 571
10. TJ Walsh, I Lutsar, T Driscoll Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children Pediatr Infect Dis J 21 2002 240 248
11. R Herbrecht, DW Denning, TF Patterson Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415
12. M Ruhnke, A Schmidt-Westhausen, M Trautmann In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection Antimicrob Agents Chemother 41 1997 575 577
13. M Cuenca-Estrella, TM Diaz-Guerra, E Mellado, A Monzon, JL Rodriguez-Tudela Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain Eur J Clin Microbiol Infect Dis 18 1999 432 435
14. L Ostrosky-Zeichner, JH Rex, PG Pappas Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States Antimicrob Agents Chemother 47 2003 3149 3154
15. MA Pfaller, DJ Diekema, SA Messer, L Boyken, RJ Hollis, RN Jones In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood J Clin Microbiol 41 2003 78 83
16. R Ally, D Schurmann, W Kreisel A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients Clin Infect Dis 33 2001 1447 1454
17. L Ostrosky-Zeichner, AML Oude Lashof, BJ Kullberg, JH Rex Voriconazole salvage treatment of invasive candidiasis Eur J Clin Microbiol Infect Dis 22 2003 651 655
18. JR Perfect, KA Marr, TJ Walsh Voriconazole treatment for less-common, emerging, or refractory fungal infections Clin Infect Dis 36 2003 1122 1131
19. JH Rex, PG Pappas, AW Karchmer A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects Clin Infect Dis 36 2003 1221 1228
20. MA Pfaller, RN Jones, GV Doern International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents Diagn Microbiol Infect Dis 35 1999 19 25
21. O Tuil, Y Cohen An open comparative multicenter study of intravenous (IV) itraconazole versus IV fluconazole in the treatment of candidemia in non-neutropenic patients Crit Care 7 suppl 2 2003 S63 S64